- Media Release /Approvals based on data from the JUNIPERA trial, showing that Cosentyx® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients1 with…
- Media Release /Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-…
- Media Release /In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than…
- Media Release /Phase 3 ASCLEPIOS I/II trials and the ALITHIOS open-label extension demonstrated the efficacy and safety of continuous Kesimpta® (ofatumumab) treatment and in those switched from teriflunomide, with…
- Story /
Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.
- Story /
A new type of medicine that targets RNA was discovered by accident and could change the way some diseases are treated.
- Story /
Technology used to tag friends on social media could change the way drug discovery is done.
- Story /
Heart failure affects 26 million people worldwide. Half die within five years of diagnosis. There's been a lack of progress in finding more effective medications. Advances in understanding mean new options for patients and caregivers.
- Story /
Two scientists from Basel are trying to shed light on why myopia is impacting more and more people.
- Media Library /
Pagination
- ‹ Previous page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- …
- 277
- › Next page